News December 13 2018

Pixium Vision awarded Galien Prize 2018 for research with PRIMA system

Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, announces today that it has been awarded the Prix Galien 2018 in the "Research Project" category for its PRIMA device for the treatment of dry Age-related Macular Degeneration (AMD). The Galien Foundation attributes this award to Pixium Vision in recognition of the innovative technology of its PRIMA wireless sub-retinal implant, a "brain-machine" interface applied to the eye to create bionic vision in the treatment of persons with dry AMD. The PRIMA device was chosen from a selection of premier projects supported by prestigious academic institutions. Khalid Ishaque, CEO of Pixium Vision, comments: "It is with pleasure that our entire team of scientific, engineering and medical researchers receives this prestigious award. The Galien Award attests to the very innovative nature of our PRIMA technology owing to elicit visual perception for patients with dry AMD. We are extremely honoured that the Galien Foundation recognizes PRIMA's major technological and medical advances, which offer new possibilities in the field of bionic vision for the treatment of retinal diseases. We would like to thank the first patients in our clinical trial for their contribution in this breakthrough human endeavour, which will enable us to continue pursuit of our mission." "We are proud to accompany Pixium Vision in developing its breakthrough technology, today awarded the Galien Prize. We congratulate the whole team for this highly valuable scientific recognition." Created as a "pharmaceutical research award" in France in 1970, the prestigious Prix Galien is recognised by the French authorities for its public interest and has an international reputation. Each year, the Prix Galien recognises the best healthcare innovations in five categories: pharmaceutical products, medical systems, e-health, patient care and research. The Prix Galien is awarded by a jury comprised of 50 international experts in healthcare. Their independence, authority and reputation confirm the excellence and credibility of the Galien Prize.

News December 12 2018

Magisto named a “Cool Vendor” in artificial intelligence for small and midsize businesses Gartner

Magisto, a leading provider of A.I.-powered social video creation and marketing solutions, today announced that it has been included as a "Cool Vendor" in the Cool Vendors in Artificial Intelligence for Small and Midsize Businesses report by Gartner, Inc. Based on primary research data, the Cool Vendors selected for this report are examples of the unique implementations of A.I. to develop products that address the needs of over 99 percent of businesses in almost every domestic market. Magisto offers a smart video editing application for businesses around the world, who utilize the power of A.I. to create and deploy video marketing creative with unprecedented ease, agility, speed and Return on Attention (ROA). Key findings of the report include: Artificial intelligence (A.I.) opportunities in the small and midsize business (SMB) space continue to expand, with higher potential among companies with less than ten years of tenure and business operations A.I. companies seeking to penetrate the SMB space are targeting areas such as automated accounting and lawyer services, marketing and e-commerce Cost optimization and time reduction around tasks that can be automated are key to attracting SMB interest “We consider our inclusion in the Cool Vendor report by Gartner a confirmation of our mission to enable entrepreneurs to leverage groundbreaking A.I. to unlock the power of video and boost business growth,” said Oren Boiman, CEO of Magisto. “At the same time that video is needed more frequently by SMBs, it becomes more complicated to authentically produce. Magisto’s unique A.I. eliminates complexity while raising the bar of content performance and quality. It is A.I. that turns the art of video creation, into data-driven science.” According to the report, “By 2020, artificial intelligence startups will increase their small and midsize business (SMB) focus by 35 percent, up from less than 5 percent today.” Magisto announces this inclusion briefly after the launch of their latest product, Chant, a new app designed to help businesses boost their growth on social media. Chant offers powerful content ideation, fully customizable video production, and native distribution and engagement insights to power social media marketing for small businesses and entrepreneurs looking to leverage video content for growth on social media. “With the recent launch of Chant, we’re delivering a truly revolutionary product that will change the face of the social video marketing industry and further enhance our market position,” continued Boiman. Chant is available for download from the Apple App Store and is being offered through a free account or a Professional subscription. To learn more, visit: For more information or to get started with Magisto for Business, download in the Apple App Store or visit

News December 12 2018

Hill-Rom & EarlySense launch patient monitoring technology for Centrella Smart+ beds

Hill-Rom, a global provider of medical technologies and hospital bed manufacturer, announced that EarlySense, developer of contact-free continuous monitoring solutions across the care continuum, has integrated its continuous contact-free heart rate and respiratory rate sensing and analytics technology into Hill-Rom's Centrella Smart+ bed platform. The Centrella bed, which offers optimized patient safety, enhanced patient satisfaction, and advanced caregiver-focused technology, now allows for continuous monitoring of patients' heart and respiratory rates over 100 times per minute without ever touching the patient. EarlySense technology alerts clinicians to potential patient deterioration events much earlier than traditional monitoring methods, enabling health teams to intervene and avoid "failure to rescue" scenarios more effectively. Specific improved clinical outcomes demonstrated with this technology include helping reduce mortality related to "code blue" events by 83 percent1, and cardiac arrests by 86 percent.2 In addition, clinicians reported overall hospital length-of-stay was reduced by 9 percent2 and ICU days by 45 percent.2 Several EarlySense customers have reported that the system also assisted with early detection of sepsis, a condition that, when not identified and treated rapidly, may be life-threatening. "Hill-Rom's Centrella bed is transforming inpatient care by integrating advanced sensing and analytics into the bed, offering a complete patient safety platform to assist clinicians in providing the highest level of care," said John Groetelaars, president and CEO of Hill-Rom. "EarlySense has been used to effectively monitor close to a million patients, positively affecting patient outcomes. By integrating the EarlySense technology into our Centrella beds, we are ushering in a new era in quality of care, whereby all patients can be continuously monitored throughout their entire hospital stay." "No patient should deteriorate without prior warning in the hospital environment. Continuous vital signs measurement should be the standard of clinical practice in the United States," said Dr. Frank Overdyk, a Charleston, S.C.-based anesthesiologist and expert on respiratory compromise. "Events such as opioid-induced respiratory depression and loss of life from failure-to-rescue are no longer acceptable given the availability of continuous vital signs monitoring." "We are proud to be Hill-Rom's exclusive bed integration and nurse call communication partner, making our sensing and analytics technology available for more hospital patients and ensuring timely, effective clinical intervention is achieved," said Avner Halperin, co-founder and CEO of EarlySense. "Integrating EarlySense monitoring capabilities with the Hill-Rom Centrella bed platform will advance our collective aspiration of having every patient in every hospital continuously monitored for safe, data-driven care, with the potential to save thousands of lives and significant costs for the healthcare system."

News December 11 2018

BioCatch brings behavioural biometrics to ACI Worldwide

A new partnership between real-time electronic payment and banking solutions provider, ACI Worldwide, and behavioural biometrics firm, BioCatch, plans to deliver better online and mobile fraud prevention to banking customers, reports David Penn at Finovate. Along with the analytic capabilities of ACI Worldwide’s UP Payments Risk Management, BioCatch’s behaviour assessment technology will help institutions defend themselves and their customers from a growing variety of cyberthreats. ACI Worldwide global director for Payments Intelligence & Risk Solutions Cleber Martins points to threats like account takeover, social engineering, and bots as the main obstacles for institutions that are attempting to provide “enriched customer experience(s)”.“As online and mobile banking proliferates, fraudsters are consistently finding new ways to infiltrate banks’ systems, creating havoc for consumers and businesses alike,” BioCatch CTO and founder Avi Turgeman says. “By using behavioural data to distinguish between a genuine customer and a fraudster – whether human or non-human – we are able to detect fraudulent activity in real-time and protect consumers.” Founded in 2011 and headquartered in Israel, BioCatch has raised $41.6 million in funding, and includes Blumberg Capital, OurCrowd, and Maverick Ventures Israel among its investors. In October, the company announced that it was partnering with seven, tier-one Latin American banks in Brazil, Chile, Colombia, and Mexico. Earlier this year, BioCatch teamed up with ForgeRock, offering its behavioural biometrics solution as an integrated module to ForgeRock’s platform. ACI Worldwide powers electronic payments for more than 5,000 institutions globally, including more than 1,000 of the world’s largest financial institutions and service providers. Founded in 1975 and based in Naples, Florida, ACI Worldwide has a market capitalisation of $3 billion.

News December 11 2018

Jerusalem Venture Partners leads $22.5m round in Quali to accelerate delivery of public and private cloud environments-as-a-service

Quali, the leader in delivering environments-as-a-service for cloud and DevOps automation, today announced a $22.5M Series-C funding round led by venture firm Jerusalem Venture Partners (JVP) and with participation from existing and new investors. With more than 200 customers worldwide including several Tier-1 enterprises, service providers and technology vendors, Quali's CloudShell platform is the industry leader in self-service environments for a variety of use-cases including DevOps automation, technical sales demos as well as cyber security and compliance. The funding allows Quali to further increase their momentum in the enterprise accelerating growth in cloud, security and DevOps use-cases. Over the past two years, the company has demonstrated high double-digit annual recurring revenue (ARR) growth and expanded into the enterprise. It has added new customer logos across a variety of segments, including the likes of Bank of America, Wells Fargo, Department of Defense and IBM, among others. The company has also transitioned to a subscription-led offering from a perpetual license-based sales approach with more than 70 percent of its revenues coming from subscription. Finally, the company has been able to dramatically expand the use-cases that are enjoying significant ROI and lower TCO as a result of implementing CloudShell. With this investment JVP joins the Quali board with Yoav Tzruya, JVP's General Partner, taking on the role of Board Chairman. Lior Koriat, CEO and Boaz Dinte, Managing Partner at Evergreen Ventures will continue to serve on the board. The board observers would also include representation from Dell Ventures and Kreos Capital. "Quali is a proven category leader in the Public and Private Cloud Automation category. With multiple companies addressing the global trend of digital transformation, we constantly witness organizations struggling with streamlining ever-increasing complex deployments. We believe the need for CloudShell will continue to grow," said Yoav Tzruya, General Partner at JVP. "We are encouraged to see existing customers re-engage to deploy more use-cases, as well as additional industries and geographies that are engaging with the company." Quali's CloudShell-based solutions improve productivity of dev/test engineering organizations, accelerate the sales cycles for selling organizations and help improve the security and compliance posture for security teams. Its blueprint-based, self-service approach has been demonstrated to increase productivity by 30 percent, cut down costs by 40 percent and increase infrastructure efficiency by more than 30 percent. "We're seeing a strong uptake of our solutions with hundreds of customers globally as they invest in digital transformation initiatives," said Lior Koriat, CEO of Quali. "We're quite pleased to raise this new round of funding and welcome the investment from JVP that has a demonstrated track record of building great companies. The Quali CloudShell platform is a proven leader in the industry and this new round allows us to accelerate our go-to-market and increase our innovation velocity." In addition to JVP, existing investors including Dell Ventures, Kreos Capital, Evergreen Ventures, Gemini Israel Ventures, and ORR Partners participated in the round. As part of this expanded funding, Quali intends to expand its sales footprint in the United States with new offices in the city of Austin. About Quali Quali is a software company focused on automation and orchestration software to deliver environments-as-a-service for digital transformation initiatives aligned with cloud, DevOps and Security. Its industry-leading CloudShell platform delivers helps enterprises and service providers increase productivity and efficiency for engineering, sales and security organizations while cutting costs dramatically. Quali's customers include several of the Fortune 500 and the Global 100. More information about Quali is available at

News December 6 2018

Biom’up successfully closes a €7.67m private placement financing

Biom’up, a specialist in surgical hemostasis, announces the success of its private placement financing of €7.67 million through a capital increase by the issuance of new shares without preferential subscription rights for the benefit of a category of beneficiaries (the "Offering"). The Company sold 1,597,332 new shares at a price of €4.80 per share, representing a discount of approx. 2% to the closing share price on December 5, 2018 (€4.90 per share). The Offering represents 12.61% of the Company’s existing share capital. The net proceeds of the Offering will allow the Company to finance the continuation and ramp up of clinical development for HEMOBLASTTM Bellows in abdominoplasty surgery, knee surgery and spinal surgery, the continuing expenditures for the construction of the new production plant near the existing site, and the ongoing efforts relating to the HEMOBLAST Bellows commercialization in the United States and Europe (sales force deployment, ramping up efforts devoted to marketing and training practitioners) along with the Company’s ordinary operating activities. Etienne Binant, Biom’up’s Chief Executive Officer, commented: I would like to sincerely thank all the investors who made this raise a success and in particular Arbevel et Athyrium who are once again demonstrating their trust in the Company. In the context of challenging financial market conditions, being able to execute such a transaction further testifies to investor confidence in our positioning and business model. These funds will now reinforce our cash position and allow us to continue the clinical development of HEMOBLAST Bellows and its commercialization, as well as associated means of production.   About HEMOBLAST HEMOBLAST Bellows is a hemostatic product to control bleeding in a broad range of surgical procedures, such as cardiac surgery, general surgery, and orthopedic surgery, etc. Biom’up conducted a successful clinical trial in the United States with 412 patients admitted to cardio-thoracic, abdominal or orthopedic (lower limb) surgeries which met all of its primary and secondary endpoints. Given the compelling preliminary results (93% effectiveness at 6 minutes, compared with 74% for the control arm), the Independent Data Monitoring Committee (IDMC) unanimously recommended to stop the study after an interim analysis of the data, which allowed the company to accelerate the submission of its filing for premarket approval (PMA) to regulatory authorities in June 2017. After obtaining expedited FDA approval for HEMOBLAST Bellows in December 2017, 7 months ahead of original plan, Biom’up’s efforts are focused on industrial and commercial activities and the recruitment of sales and marketing teams in the U.S. to prepare the planned commercial roll-out of our lead product in the United States. On July 12, 2018, Biom’up obtained CE Marking for its HEMOBLAST Bellows Laparoscopic Applicator designed to deliver the HEMOBLAST Bellows powder in minimally-invasive procedures. This has opened the way for the Company in a new market segment representing approximately 500,000 surgeries per year in Europe. In addition, on July 2, 2018 the Company filed a PMA supplement to obtain approval for HEMOBLAST Bellows for all laparoscopic surgical procedures in the United States. About Biom’up Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’up designs hemostatic products based on patented biopolymers that aim to simplify surgical procedures in numerous specialties (spine, cardiothoracic, general, orthopedic, plastic) and give patients a better quality of life. Since its creation, Biom’up has benefited from the support of prominent European investors such as Bpifrance, Innobio, Gimv, Lundbeckfond, Mérieux Participation, SHAM and ACG, as well as all the company’s managers, who have invested €2 million in equity. Biom’up successfully completed its IPO on Euronext Paris, raising €42.5 million in October 2017. This has been followed by a €16 million capital increase in February 2018 and a €25 million bond financing agreement with Athyrium Opportunities III Acquisition LP, a US fund specializing in innovative companies in the healthcare sector, in March 2018.